Neuberger Berman Group
CRSP icon

Neuberger Berman Group’s CRISPR Therapeutics CRSP Stock Holding History

Neuberger Berman Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Buy
+4,366
New +$230K ﹤0.01% 2110
2021
Q2 		– Sell
-3,240
Closed -$395K – 1769
2021
Q1 		$395K Buy
3,240
+648
+25% +$97.8K ﹤0.01% 1538
2020
Q4 		$407K Buy
2,592
+153
+6% +$18.1K ﹤0.01% 1444
2020
Q3 		$211K Buy
+2,439
New +$216K ﹤0.01% 1544

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Neuberger Berman Group's CRSP Position: Q2 2026 in Review

Neuberger Berman Group opened a new position in CRISPR Therapeutics (CRSP) in Q2 2026: 4,366 shares worth $238K. The stake represents ﹤0.01% of the portfolio and ranks #2110 among its holdings. This is a return to the name: Neuberger Berman Group previously reported a position in CRSP as recently as Q1 2021.

Neuberger Berman Group first reported a position in CRSP in Q3 2020 and has held it in 4 quarters since. The position peaked at $407K in Q4 2020. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Neuberger Berman Group held 4,366 shares of CRISPR Therapeutics worth $238K as of Q2 2026.
  • CRISPR Therapeutics was a new Neuberger Berman Group position in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Neuberger Berman Group's portfolio in Q2 2026, its #2110 holding.
  • Neuberger Berman Group first reported a position in CRISPR Therapeutics in Q3 2020 and has held it in 4 quarters since.
  • Neuberger Berman Group's CRISPR Therapeutics position peaked at $407K in Q4 2020.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Neuberger Berman Group's 13F filing for Q2 2026, filed 13 Aug 2026.